CTI BioPharma Corp. (NASDAQ:CTIC) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Wednesday.

Separately, Jefferies Group LLC started coverage on shares of CTI BioPharma Corp. in a report on Tuesday, September 12th. They set a “buy” rating and a $7.50 price objective on the stock.

CTI BioPharma Corp. (NASDAQ:CTIC) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.63. CTI BioPharma Corp. had a negative net margin of 136.76% and a negative return on equity of 418.99%. The company had revenue of $22.23 million for the quarter.

COPYRIGHT VIOLATION WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/13/cti-biopharma-corp-ctic-rating-lowered-to-strong-sell-at-valuengine.html.

In related news, Director Richard L. Love sold 14,600 shares of the company’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $3.21, for a total value of $46,866.00. Following the sale, the director now owns 84,318 shares of the company’s stock, valued at $270,660.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 8.08% of the company’s stock.

A hedge fund recently bought a new stake in CTI BioPharma Corp. stock. WASHINGTON TRUST Co bought a new stake in CTI BioPharma Corp. (NASDAQ:CTIC) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 31,400 shares of the biopharmaceutical company’s stock, valued at approximately $104,000. WASHINGTON TRUST Co owned 0.11% of CTI BioPharma Corp. as of its most recent SEC filing. 42.87% of the stock is owned by institutional investors.

About CTI BioPharma Corp.

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Receive News & Stock Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related stocks with our FREE daily email newsletter.